Research Library / Neurocognitive / Adamax
Neurocognitive researchAdamax
Semax-related analog · Experimental nootropic peptide
An experimental peptide marketed for cognition and focus. The listed community example (published community titration · weeks 1–2) describes 300 mcg per administration, once daily, via subcutaneous — anecdotal; this is not a validated dosing recommendation. An illustrative 10 mg vial at an assumed 2 mL final volume yields 5 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 10mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 5mg/mL · conditional arithmetic
- One U-100 marking
- 50mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
No established clinical dose, route, frequency or duration
No direct Adamax human study identified; similarly named optimizer papers are unrelatedPubMed search — Adamax peptideNo established clinical dose, route, frequency or duration
No registered Adamax trial identified in this reviewClinicalTrials.gov searchNo established clinical dose, route or frequency
Medsafe classification submission discusses Adamax among ACTH analogues; not evidence of efficacy or approvalMedsafe classification submission, June 2025Reported schedule context
- Range
- 300–1,000 mcg/day in a published community schedule
- Frequency
- Once daily in that schedule
- Route
- Subcutaneous; intranasal reports also exist
- Reported half-life
- Not established in humans
- Reported cycle
- 8-week community titration example; no validated cycle or off-cycle
A commercial/community schedule, not clinical evidence or a recommended escalation. Route, timing, tolerance and superiority to Semax are unproven; nasal spray amounts cannot be inferred from syringe units.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Published community titration · Weeks 1–2 | 300 mcg | 300 mcg/day | Once daily | Timing not established | Subcutaneous — anecdotal | Community-reported |
| Published community titration · Weeks 3–4 | 500 mcg | 500 mcg/day | Once daily | Timing not established | Subcutaneous — anecdotal | Community-reported |
| Published community titration · Weeks 5–6 | 750 mcg | 750 mcg/day | Once daily | Timing not established | Subcutaneous — anecdotal | Community-reported |
| Published community titration · Weeks 7–8 | 1,000 mcg | 1,000 mcg/day | Once daily | Timing not established | Subcutaneous — anecdotal | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
33.333 example portions per vial
33 full amounts; 0.1 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
300 mcg community arithmetic example · 5 mg/mL · 0.06 mL · 6 units
The linked community schedule uses 3 mL; this site uses a 2 mL arithmetic example for 10 mg vials. At 5 mg/mL: 300 mcg = 6 units; 500 mcg = 10 units; 750 mcg = 15 units; 1,000 mcg = 20 units. These U-100 values are not nasal-spray measurements. No Adamax-specific diluent compatibility, stability or beyond-use period is established. BAC-water vial examples are community conventions. A single community report describes incomplete dissolution in saline compared with BAC water; this is not a controlled stability comparison. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
10 mg or 5 mg vial · 2 mL assumed final solution volume per vial · community titration, not trial-derived
Vial counts and final solution totals below use the selected 10 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg | Once daily | 2.1 mg/week |
| Weeks 3–4 | 500 mcg | Once daily | 3.5 mg/week |
| Weeks 5–6 | 750 mcg | Once daily | 5.25 mg/week |
| Weeks 7–8 | 1 mg | Once daily | 7 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 8 weeks · 10 mg vial example | 35.7 mg | 4 × 10 mg |
| 8 weeks · 5 mg vial example | 35.7 mg | 4 × 10 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 8 weeks · 10 mg vial example | 8 mL | Not established |
| 8 weeks · 5 mg vial example | 8 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 8 weeks · 10 mg vial example | 56 |
| 8 weeks · 5 mg vial example | 56 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
8 weeks · 10 mg vial example: 33.3 / 20 / 13.3 / 10 administrations at the respective phase amounts
8 weeks · 5 mg vial example: 16.7 / 10 / 6.7 / 5 administrations at the respective phase amounts
Applies to the original planning basis above; not a product stability period.
This published community escalation has not been clinically validated and is not a loading phase. Totals assume 56 daily administrations, no transfer loss and 2 mL per vial. Fractional vial-life figures describe arithmetic only. Liquid totals are conditional final-volume arithmetic; diluent identity and bottle quantities are not established. The source's 3 mL setup uses different volumes. No validated off-cycle or extension is established.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Adamax · Semax-related analog · Experimental nootropic peptide
- Evidence / status
- No direct clinical evidence. Not FDA approved; no established medical protocol
- Clinical route, frequency & duration
Direct-evidence review · October 15, 2026: No established clinical dose, route, frequency or duration
Trial-registry review · October 15, 2026: No established clinical dose, route, frequency or duration
Regulatory background, not a dosing study: No established clinical dose, route or frequency
- Community purpose
- Focus, cognition, memory and neuroplasticity discussions. These are community claims, not demonstrated Adamax benefits.
- Reported timing / route
- Once daily in that schedule · Subcutaneous; intranasal reports also exist. Schedule-specific timing remains in the Community tab.
- Reported half-life
- Not established in humans · community-reference context, not a shelf life.
- Reported cycle
- 8-week community titration example; no validated cycle or off-cycle. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
BAC-water vial examples are community conventions. A single community report describes incomplete dissolution in saline compared with BAC water; this is not a controlled stability comparison.
Other vehicles and approaches discussed
Some vendors suggest acidified media. Neither acid, PBS, saline nor a mixed-diluent ratio is validated as a universal Adamax preparation.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Limited and conflicting reports; stability unknown
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Limited and conflicting reports; stability unknown
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Marketed as a modified Semax-related ACTH analog; direct mechanism is unestablished
An experimental peptide marketed for cognition and focus. Direct Adamax clinical evidence was not identified in the October 15, 2026 review; Semax findings do not establish Adamax efficacy, potency, or duration.
Community-reported purpose
Focus, cognition, memory and neuroplasticity discussions. These are community claims, not demonstrated Adamax benefits.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Direct-evidence review · October 15, 2026
Protocol: No established clinical dose, route, frequency or duration
Population: No direct Adamax human study identified; similarly named optimizer papers are unrelated
Read the cited evidenceTrial-registry review · October 15, 2026
Protocol: No established clinical dose, route, frequency or duration
Population: No registered Adamax trial identified in this review
Read the cited evidenceRegulatory background, not a dosing study
Protocol: No established clinical dose, route or frequency
Population: Medsafe classification submission discusses Adamax among ACTH analogues; not evidence of efficacy or approval
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Adamax-specific adverse-event rates, interactions, long-term safety and human half-life are not established. Chemical identity and formulation can differ between marketed products. Semax data cannot validate Adamax use, and an absence of documented harms does not establish safety.
Development and regulatory status
Not FDA approved; no established medical protocol
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Adamax?
An experimental peptide marketed for cognition and focus. Direct Adamax clinical evidence was not identified in the October 15, 2026 review; Semax findings do not establish Adamax efficacy, potency, or duration.
Marketed as a modified Semax-related ACTH analog; direct mechanism is unestablished
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
8-week community titration example; no validated cycle or off-cycle
Which diluent and storage period should this material use?
BAC-water vial examples are community conventions. A single community report describes incomplete dissolution in saline compared with BAC water; this is not a controlled stability comparison.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapePubMed search — Adamax peptide: Direct-evidence review · October 15, 2026
- Clinical / regulatory / evidence landscapeClinicalTrials.gov search: Trial-registry review · October 15, 2026
- Clinical / regulatory / evidence landscapeMedsafe classification submission, June 2025: Regulatory background, not a dosing study
- Community/vendor report — unvalidatedAdamax saline/BAC report
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.